Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to Keytruda (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.
Vitamin D deficiency could be the reason African American men experience more aggressive prostate cancer at a younger age compared with European American men, research from Cedars-Sinai Cancer suggests. The multi-institutional study, published in Cancer Research Communications, a journal of the American Association for Cancer Research, could pave the way for revised nutritional guidelines.
The FIGHT-207 trial, led by Jordi Rodon, associate professor of Investigational Cancer Therapeutics at MD Anderson Cancer Center, demonstrated promising early signs of clinical benefit and revealed potential mechanisms of primary and secondary resistance following treatment with the selective FGFR inhibitor pemigatinib in patients with advanced FGFR-altered solid tumors.
Two trials led by Timothy A. Yap, associate professor of Investigational Cancer Therapeutics at MD Anderson Cancer Center, showed encouraging results for treating solid tumors with DNA damage response alterations using a combination of PARP and ATR inhibitors. Notably, anti-tumor activity was seen in patients with tumors that had previously shown resistance to PARP inhibitors or platinum-based therapies.
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a phase I trial led by researchers at MD Anderson Cancer Center. The first-in-human study was presented today at the 2023 American Association for Cancer Research annual meeting.
The CD70-targeting allogeneic CAR T-cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma, according to results of a phase I trial led by researchers at MD Anderson Cancer Center and presented at the American Association for Cancer Research annual meeting.
A large retrospective study conducted by physician researchers from Roswell Park Comprehensive Cancer Center shows benefits of chemotherapy for many patients with early-stage breast cancer with rare variant histology, or tumor anatomy. These findings were presented by first author Arya Mariam Roy during the American Association for Cancer Research annual meeting.
MD Anderson Cancer Center researchers have identified recent developments in effective combination therapies for patients with BRAF V600E mutations, an approach to identify cancer biomarkers in extracellular vesicles, therapeutic strategies for improving treatment responses in non-small cell lung cancer, and a novel combination therapy to overcome treatment resistance in a subset of patients with acute myeloid leukemia.
A new approach to chimeric antigen receptor T-cell therapy has shown great promise against small cell lung cancer in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.
A University of Rochester/Wilmot Cancer Institute team discovered the molecule responsible for guiding T cells toward tumors.
